Furthermore, the successful treatment of IBD in patients with TNFα chimeric monoclonal antibodies (cA2 or infliximab) established a clear association of the role of this cytokine in the pathogenesis of IBD [17]. The gene discussed is CA2; the disease is inflammatory bowel disease.